NICE recommends Lixiana (edoxaban) for prevention of stroke and systemic embolism- Daiichi Sankyo
The National Institute of Health and Care Excellence (NICE) has issued a Final Appraisal Determination for Lixiana (edoxaban) from Daiichi Sankyo for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. Draft guidance states: "Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, including: congestive heart failure, hypertension, diabetes, prior stroke or transient ischaemic attack and age 75 years or older".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins